Gut and Liver 2009; 3(1): 20-25 https://doi.org/10.5009/gnl.2009.3.1.20 Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study
Author Information
Sang Hoon Ahn*, Hyun Woong Lee, Yong Soo Kim*, Ja Kyung Kim*, Kwang-Hyub Han*, Chae Yoon Chon*, and Young Myoung Moon*
Department of Internal Medicine, *Yonsei University College of Medicine, Yonsei Institute of Gastroenterology, Chung-Ang University College of Medicine, and Brain Korea 21 Project for Medical Science, Seoul, Korea

Young Myoung Moon
© The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. All rights reserved.

Abstract
Background/Aims: Interferon beta (IFN-Ղ) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-Ղ (IFN-Ղ-1a) plus oral ribavirin versus interferon alpha (IFN-Ձ) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naïve patients were randomized into two equal-sized treatment groups. Both IFN-Ղ-1a (44Ռg) and IFN-Ձ (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-Ղ-1a group and IFN-Ձ groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-Ղ-1a group than in the IFN-Ձ group, and there were more HCV genotype 1 patients in the IFN-Ղ-1a group (eight versus seven). The IFN-Ղ-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-Ղ-1a and ribavirin and that of IFN-Ձ and ribavirin. (Gut and Liver 2009;3:20-25)
Keywords: Hepatitis C; Treatment outcome; Interferons; Prospective studies
Abstract
Background/Aims: Interferon beta (IFN-Ղ) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-Ղ (IFN-Ղ-1a) plus oral ribavirin versus interferon alpha (IFN-Ձ) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naïve patients were randomized into two equal-sized treatment groups. Both IFN-Ղ-1a (44Ռg) and IFN-Ձ (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-Ղ-1a group and IFN-Ձ groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-Ղ-1a group than in the IFN-Ձ group, and there were more HCV genotype 1 patients in the IFN-Ղ-1a group (eight versus seven). The IFN-Ղ-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-Ղ-1a and ribavirin and that of IFN-Ձ and ribavirin. (Gut and Liver 2009;3:20-25)
Keywords: Hepatitis C; Treatment outcome; Interferons; Prospective studies
Search for
Services
Archives